Loading...

EQRx, Inc.

EQRX•NASDAQ
Healthcare
Biotechnology
$2.34
$-0.05(-2.09%)

EQRx, Inc. (EQRX) Stock Overview

Explore EQRx, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.6/100

Key Financials

Market Cap1.1B
P/E Ratio5.40
EPS (TTM)$-0.55
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.97

EQRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of EQRx, Inc. (EQRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.97.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 5.40 and a market capitalization of 1.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for EQRXStats details for EQRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for EQRXAnalyst Recommendations details for EQRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

CEO

Melanie I. Nallicheri

Employees

362

Headquarters

50 Hampshire Street, Cambridge, MA

Founded

2021

Frequently Asked Questions

;